Results 11 to 20 of about 54,010 (241)
Pharmacogenomics, 2010 Irinotecan is a camptothecin analog used as an anticancer drug. Severe, potentially life-threatening toxicities can occur from irinotecan treatment. Although multiple genes may play a role in irinotecan activity, the majority of evidence to date suggests that variation in expression of UGT1A1 caused by a common promoter polymorphism (UGT1A1*28) is ...
Sharon, Marsh, Janelle M, Hoskins
openaire +4 more sources
Irinotecan-gut microbiota interactions and the capability of probiotics to mitigate Irinotecan-associated toxicity [PDF]
BMC Microbiology, 2023 Background Irinotecan is a chemotherapeutic agent used to treat a variety of tumors, including colorectal cancer (CRC). In the intestine, it is transformed into SN-38 by gut microbial enzymes, which is responsible for its toxicity during excretion ...
Marwa S. Mahdy +7 more
doaj +2 more sources
BMC Gastroenterology, 2018 Background For patients with advanced gastric cancer (AGC), second-line chemotherapy regimen remains controversial. The efficacy and safety of irinotecan-containing doublet treatment and irinotecan monotherapy were compared in this systematic analysis ...
Liuting Yang +7 more
doaj +2 more sources
Irinotecan-Induced Dysarthria [PDF]
Case Reports in Oncology, 2012 Colorectal carcinomas are among the most common tumor types and are generally treated with palliative chemotherapy in case of metastatic disease. Here, we describe the case of a 46-year-old patient with metastatic rectal carcinoma who received second-line therapy with irinotecan and developed isolated transient dysarthria (with normal MR imaging of the
Dressel, A.J. +4 more
openaire +5 more sources
Protective role of Lactobacillus plantarum A7 against irinotecan-induced genotoxicity [PDF]
Avicenna Journal of Phytomedicine, 2016 Objective: Irinotecan is a botanical derivative and an anti-cancer drug with cytotoxic and genotoxic effects. The present study evaluated the effect of Lactobacillus plantarum A7 on the genotoxic activity of irinotecan in a hepatocellular carcinoma cell ...
Soheila Sepahi +4 more
doaj +1 more source
Hepatology, EarlyView., 2022 Phase 1b study of anlotinib combined with TQB2450 in pretreated advanced biliary tract cancer and biomarker analysis. Abstract Background and Aims We evaluated the efficacy and safety of the antiangiogenic tyrosine kinase inhibitor anlotinib plus TQB2450, a programmed deathâligand 1 inhibitor in pretreated advanced biliary tract cancers (BTCs ...
Jun Zhou +13 more
wiley +1 more source
Bevacizumab plus Irinotecan-Based Regimens in the Treatment of Metastatic Colorectal Cancer [PDF]
, 2010 Objectives: Bevacizumab is a monoclonal antibody that directly inhibits vascular endothelial growth factor, a key regulator of angiogenesis. Bevacizumab significantly improves progression-free and/or overall survival in metastatic colorectal cancer in ...
Volker Heinemann +3 more
core +1 more source
Effective second-line treatment with cetuximab and bevacizumab in a patient with hepatic metastases of colorectal cancer and hyperbilirubinemia [PDF]
, 2007 Background: Irinotecan-based second-line chemotherapy of metastatic colorectal cancer (CRC) is effective, it might, however, be contraindicated in cases of severe liver dysfunction due to advanced liver metastases.
Moosmann, Nicolas +4 more
core +1 more source
Frontiers in Oncology, 2021 BackgroundAt present, patients with metastatic breast cancer (MBC) have few treatment options after receiving anthracyclines and taxanes. Studies have shown that irinotecan has modest systemic activity in some patients previously treated with ...
Jiaojiao Suo +12 more
doaj +1 more source
PLoS ONE, 2015 Irinotecan, an analogue of camptothecin, is frequently used as a single agent or in combination with other anticancer drugs for the treatment of colorectal cancer. However, the drug resistance of tumors is a major obstacle to successful cancer treatment.
Seung Ho Choi +4 more
doaj +1 more source